-
Product Insights
NewXerostomia – Drugs In Development, 2024
Empower your strategies with our Xerostomia – Drugs In Development, 2024 report and make more profitable business decisions. Xerostomia is defined as dry mouth resulting from reduced saliva flow. It is caused by medications, age, cancer treatment, injury, dehydration, and chewing or smoking tobacco. Symptoms include dysgeusia, fungal infections, bad breath, tongue ulcers, problems speaking, and sticky saliva. Treatment includes medications that stimulate saliva production. The Xerostomia drugs in development market research report provide comprehensive information on the therapeutics under development...
-
Product Insights
NewWilson Disease – Drugs In Development, 2024
Empower your strategies with our Wilson Disease – Drugs In Development, 2024 report and make more profitable business decisions. Wilson disease is a rare autosomal recessive inherited disorder of copper metabolism that is characterized by excessive deposition of copper in the liver, brain, and other tissues. Symptoms include abdominal pain, jaundice, problems with speech and swallowing, and muscle stiffness. Treatment includes chelators and vitamin E supplements. The Wilson Disease drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
NewLeber Congenital Amaurosis (LCA) – Drugs In Development, 2024
Empower your strategies with our Leber Congenital Amaurosis (LCA) – Drugs In Development, 2024 report and make more profitable business decisions. Leber congenital amaurosis (LCA) is a genetic eye disorder that primarily affects the retina, which is the specialized tissue at the back of the eye that detects light and color. This condition is the most common cause of inherited blindness in childhood. Symptoms include vision loss, roving eye movements, deep-set eyes, developmental delay, epilepsy, and motor skill impairment. The Leber...
-
Product Insights
NewSicca Syndrome (Sjogren) – Drugs In Development, 2024
Empower your strategies with our Sicca Syndrome (Sjogren) – Drugs In Development, 2024 report and make more profitable business decisions. Sjogren's syndrome is an autoimmune disease. It involves the inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling, and stiffness. Predisposing factors include age, sex, and rheumatic disease. The Sicca Syndrome (Sjogren) drugs in development market research report provide comprehensive...
-
Product Insights
NewRetinal Degeneration – Drugs In Development, 2024
Empower your strategies with our Retinal Degeneration – Drugs In Development, 2024 report and make more profitable business decisions. Retinal degeneration refers to a group of diseases that cause progressive damage to the cells of the retina, the light-sensitive tissue at the back of the eye crucial for vision. These conditions lead to a gradual loss of vision, which can range from mild to severe and can eventually result in blindness. There are several types of retinal degenerative diseases, including: Retinitis...
-
Product Insights
NewUveitis – Drugs In Development, 2024
Empower your strategies with our Uveitis – Drugs In Development, 2024 report and make more profitable business decisions. Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark floating spots in the vision, eye pain, redness of the eye, and sensitivity to light. The predisposing factors...
-
Product Insights
NewFrontotemporal Dementia (FTD) – Drugs In Development, 2024
Empower your strategies with our Frontotemporal Dementia (FTD) – Drugs In Development, 2024 report and make more profitable business decisions. Frontotemporal dementia (FTD) encompasses various brain disorders leading to progressive damage in the frontal and temporal lobes. It manifests in distinct ways: behavioral changes, language difficulties, or movement impairments. Symptoms range from altered social conduct, lack of empathy, and impulsivity to language struggles or motor coordination issues. FTD's exact cause remains unclear, but abnormal protein deposits in the brain are implicated....
-
Product Insights
NewRetinitis Pigmentosa (Retinitis) – Drugs In Development, 2024
Empower your strategies with our Retinitis Pigmentosa (Retinitis) – Drugs In Development, 2024 report and make more profitable business decisions. Retinitis pigmentosa refers to a group of diseases that cause a slow but progressive loss of vision. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa (Retinitis) drugs in development market research report provide comprehensive information on...
-
Product Insights
NewKeratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also called dry eye disease (DED) or dry eye syndrome (DES), is a condition in which a person experiences dryness of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses, and low levels of vitamin A. Treatment includes...
-
Product Insights
NewGlaucoma – Drugs In Development, 2024
Empower your strategies with our Glaucoma – Drugs In Development, 2024 report and make more profitable business decisions. Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow to the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, and family history of glaucoma. Signs and symptoms include...